Search Results
Surviving Chemo: A Little Planning Goes a Long Way
Just the thought of chemotherapy can be enough to make one feel sick. Toxic drugs powerful enough to kill or damage cancer cells also take their toll on healthy cells. While everyone tends to respond differently, most agree the treatments come with unpleasant side effects.
Check out these 14 tips from The Leukemia & Lymphoma Society that should help make the experience a little less uncomfortable:
Lenalidomide
Lenalidomide is FDA approved to treat patients with:
Meet the Researcher: Maria Figueroa, MD
Our “Meet the Researcher” series on The LLS Blog shares what our outstanding LLS-funded researchers are working on, the incredible impact they’re making in the fight against blood cancer, and what inspires their efforts to find better treatments and cures. Dr. Maria “Ken” Figueroa, Associate Professor and Co-Leader of the Cancer Epigenetics Research Program at Sylvester Comprehensive Cancer Center, part of the University of Miami Health System, is focused on an exciting area of research called epigenetics.
Lisocabtagene maraleucel
Lisocabtagene maraleucel is indicated for the treatment of
Ivosidenib
Ivosidenib is FDA approved for the treatment of patients with a susceptible IDH1 mutation as detected by an FDA-approved test in:
Brexucabtagene autoleucel
Brexucabtagene autoleucel is FDA approved for the treatment of
- Adult patients with relapsed or refractory mantle cell lymphoma (MCL).
This indication is approved under accelerated approval based on overall response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. - Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Rituximab and hyaluronidase human
Rituximab and hyaluronidase human is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:
Burlington Stores Raise $3.3 Million to Help Fight Blood Cancer
Burlington Stores and The Leukemia & Lymphoma Society’s (LLS) Light The Night campaign’s 16th consecutive year of partnership in the fight against blood cancers was a big success. As LLS’s #1 National Corporate Partner and Honored Friend, Burlington Stores raised $3.3 million to fund blood cancer research and help patients access lifesaving treatments and cures.
LLS “FACEBOOK LIVE” INSPIRES THE NEXT GENERATION OF SCIENTISTS
As schools and education communities across the country have had to adjust to a new way of learning online, The Leukemia & Lymphoma Society’s Pennies for Patients program (www.penniesforpatients.org), a science-based service-learning program for schools, has shifted in-person school learning events to a virtual semi-weekly STEM+ curriculum program to inspire the next generation of scientists and doctors.